First Tracks Biotherapeutics Inc Stock price
Compare with Peer Group
Is First Tracks Biotherapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.
Key metrics
First Tracks Biotherapeutics Inc Stock Analysis
Analyst Opinions
15 Analysts have issued a First Tracks Biotherapeutics Inc forecast:
Analyst Opinions
15 Analysts have issued a First Tracks Biotherapeutics Inc forecast:
Don't miss a Thing! We will send you all news about First Tracks Biotherapeutics Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
First Tracks Biotherapeutics Inc Stock News
Company Profile
First Tracks Biotherapeutics, Inc. engages in the research and development of immunology therapeutics for autoimmune and inflammatory diseases. The company is headquartered in San Diego, California and currently employs 104 full-time employees. The company went IPO on 2026-04-06. The firm's clinical-stage pipeline includes Rosnilimab, a selective pathogenic T cell depleter, for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a blood dendritic cell antigen 2 (BDCA2) modulator. Rosnilimab is an IgG1 antibody that directly targets pathogenic T cells, such as activated Tph/Tfh and T effector cells, in the periphery or inflamed tissue. Rosnilimab is designed to selectively deplete pathogenic T cells while sparing non-pathogenic T cells, including naive T cells, to preserve overall immune function and restore immune homeostasis. Its molecules have applicability across a range of autoimmune and inflammatory diseases, including gastroenterology, rheumatology and other areas.
| Head office | United States |
| Website | www.firsttracksbio.com |


